

(1)

QUTENZA® (capsaicin) 8% patch



General Resources

**Product Pipeline (/products
/pipeline)**

**Comprehensive Compliance Plan
(/assets/docs/other/Acorda
Comprehensive Compliance
Program December 2014.pdf)**

Click here to see Important Safety Information below

Qutenza® (capsaicin) 8% patch is indicated for the management of neuropathic pain associated with postherpetic neuralgia (PHN). PHN is also known as post-shingles nerve pain. Qutenza delivers medicine directly into the skin to the nerves that cause pain after shingles. A single, 1-hour application can provide up to three months of pain relief.

The active ingredient in Qutenza is a pharmaceutical grade, prescription-strength formulation of capsaicin. Qutenza is believed to provide pain reduction by acting on hyperactive pain nerves which have been damaged due to shingles.

Shingles is a disease caused by the same virus that causes chickenpox. In people with shingles, the chickenpox virus, which has been inactive in the body, returns and travels along the nerves in the skin, damaging the nerves and causing rash, blisters, and pain. In some people, this pain can continue for months or years after the shingles rash has healed.

The pain from damaged nerves may feel like a sharp, burning, tingling, shooting, or numb sensation. The risk of developing PHN increases with age (especially in people over 60) and for patients who experienced severe pain or severe rash during the acute shingles episode.

Qutenza is applied by a doctor or healthcare professional directly to the skin at the painful site, but is not for use on the face or scalp. It is the only pharmaceutical grade, prescription-strength capsaicin formulation currently available. It is non-narcotic and is unlikely to have drug-drug interaction. Qutenza can be used alone or in combination with other pain medications.

For healthcare professionals who want more information, visit www.qutenza.com (<http://www.qutenza.com>).

Important Safety Information

Treatment with Qutenza (capsaicin) must be performed only by a healthcare provider. You should never apply or remove Qutenza yourself.

Warnings and Precautions:

- Qutenza is not for use near eyes or mucous membranes. Do not sniff or inhale near the Qutenza patch as this may cause you to cough or sneeze.
- Do not touch the Qutenza patch with your hands. If you touch the patch, it may cause burning and stinging; if this occurs, tell your healthcare provider.

- Even though a numbing medicine is used on the skin before applying Qutenza, some patients may still experience substantial pain during the treatment. Tell your healthcare provider if you are experiencing pain; a cool compress or medicine for the pain can be provided to help lessen your discomfort.
- Qutenza can cause serious side effects including pain and increases in blood pressure during or right after treatment.
- Your healthcare provider should check your blood pressure during treatment with Qutenza.
- Patients who have high blood pressure that is not well controlled by medicine, or who have had recent heart problems, stroke, or other vascular problems, may be at increased risk and should discuss with their doctor whether Qutenza is right for them.
- If opioids are used to treat pain associated with the application procedure, please note that opioid treatment may affect the patient's ability to perform potentially hazardous activities such as driving or operating heavy machinery.

Side Effects:

- In clinical studies, the most common side effects of Qutenza, which occurred in 5% or more of patients, included: redness, pain, itching, or small bumps where Qutenza was applied, and nausea.
- You should tell your doctor if any side effects bother you or do not go away.

These are not all the side effects of Qutenza. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch/ (<http://www.fda.gov/medwatch/>), or call 1-800-FDA-1088.

For full Prescribing Information, please click [here](http://www.qutenza.com/_docs/qutenza_full_PI_.pdf) (http://www.qutenza.com/_docs/qutenza_full_PI_.pdf).

Qutenza® is a registered trademark of Acorda Therapeutics, Inc.

QUT5870 8/17

ABOUT ACORDA (/ABOUT)FOR PATIENTS (/PATIENTS)PRODUCTS & RESEARCH (/PRODUCTS)INVESTORS (/INVESTORS)NEWS & EVENTS (/NEWS)CAREERS (/CAREERS)

<p>Company Leadership (/about/company-leadership)</p> <ul style="list-style-type: none"> Management Team (/about/company-leadership/management-team) Board of Directors (/about/company-leadership/board-of-directors) Partnering With Acorda (/about/company-leadership/partnering) <p>Grant Program (/about/grant-program)</p> <p>Scientific Award (/about/scientific-award)</p> <p>Compliance (/about/compliance)</p> <ul style="list-style-type: none"> Acorda Compliance (/about/compliance/acorda-compliance) Biotie EFPIA Disclosures (/about/compliance/biotie-efpia-disclosures) <p>Message from BIO (/about/message-from-bio)</p> <p>Diversity and Inclusion (/about/diversity-and-inclusion)</p> <p>Contact Us (/about/contact-us)</p>	<p>Focus On Therapies (/patients/focus-on-therapies)</p> <p>In the Community (/patients/community)</p> <p>Resources (/patients/resources)</p> <p>Policy on Access to Unapproved Medicines (/patients/policy-on-access-to-unapproved-medicines)</p>	<p>Pipeline (/products/pipeline)</p> <p>ARCUS® Technology (/products/arcus-technology)</p> <p>Products (/products/products)</p> <ul style="list-style-type: none"> AMPYRA® (dalifampridine) (/products/products/ampyra) QUTENZA® (capsaicin) 8% patch (/products/products/qutenza) <p>Clinical Trials (/products/clinical-trials)</p> <p>Research & Development (/products/research-development)</p> <ul style="list-style-type: none"> CVT-301 (/products/research-development/cvt-301) SYN120 (/products/research-development/syn120) BTT1023 (timolimumab) (/products/research-development/btt1023) CVT-427 (/products/research-development/cvt-427) rHlgM22 (/products/research-development/rhlgm22) 	<p>Corporate Governance (/investors/corporate-governance)</p> <p>Stock Information (/investors/stock-information)</p> <p>Investor Events (/investors/investor-events)</p> <p>Investor News (/investors/investor-news)</p> <p>Financial Information (/investors/financial-information)</p> <ul style="list-style-type: none"> Quarterly Reports (/investors/financial-information/quarterly-reports) Annual Reports (/investors/financial-information/annual-reports) SEC Filings (/investors/financial-information/sec-filings) Analysts (/investors/financial-information/analysts) <p>Investor Resources (/investors/investor-resources)</p> <ul style="list-style-type: none"> Investor Kit (/investors/investor-resources/investor-kit) E-mail Alerts (/investors/investor-resources/e-mail-alerts) FAQs (/investors/investor-resources/faqs) IR Contact (/investors/investor-resources/contact-us) 	<p>In the News (/news/in-the-news)</p> <p>Awards (/news/awards)</p> <p>Press Releases (/news/press-releases)</p> <p>Social Media (/news/social-media)</p>	<p>Working at Acorda (/careers/working-at-acorda)</p> <p>Our Employees (/careers/our-employees)</p> <p>Benefits (/careers/benefits)</p> <p>Job Openings (/careers/job-openings)</p> <p>Internship Program (/careers/internship-program)</p> <p>Application (/careers/job-application)</p>
---	--	--	---	---	---

(/)
[PRIVACY POLICY \(/PRIVACY-POLICY\)](#) [TERMS OF USE \(/TERMS-OF-USE\)](#) [SITE MAP \(/SITE-MAP\)](#) [CONTACT US \(/CONTACT-US\)](#)